# Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis

## TL;DR

Denosumab is a promising treatment for male osteoporosis, improving bone density and patient satisfaction.

## Contribution

This review highlights denosumab's effectiveness and safety in managing osteoporosis in men.

## Key findings

- Denosumab improves bone mineral density in men with osteoporosis.
- It reduces bone turnover markers effectively.
- Higher adherence and patient satisfaction are reported with denosumab.

## Abstract

Bone is a dynamic tissue. It remodels, preserving serum calcium, repairing microdamage, and maintaining strength. Osteoporosis is caused by a decrease in bone strength, which manifests clinically as low-energy vertebral and non-vertebral fractures. Osteoporosis poses a significant public health challenge. While it's often portrayed as primarily impacting postmenopausal women, there's been growing recognition among researchers and clinicians regarding its prevalence in men. Major fracture in men has higher mortality rates than in women. Denosumab is a fully human monoclonal immunoglobulin G2 (IgG2) antibody that binds to RANKL, the principal regulator of osteoclastic bone resorption. Multiple studies suggest that denosumab is both effective and safe, exhibiting higher adherence rates and greater patient satisfaction. In this narrative review, we highlighted the effects of denosumab in men with osteoporosis, subsequent changes in bone mineral density, and bone turnover markers outlining the literature and guideline support.